Adalimumab is among the most expensive drugs in the United States, with a list price that can exceed $6,000 per month for brand Humira. For patients navigating this cost, there are several programs designed to reduce what you actually pay — but they work very differently and serve different patient populations.
Here's a clear breakdown of Humira Complete, AbbVie's patient assistance program, and the biosimilar manufacturers' programs — including which one fits your situation.
The Three Tiers of Humira Cost Assistance
There are three distinct types of assistance available for adalimumab:
- Copay cards — reduce the copay for commercially insured patients; fast and easy but not available for Medicare/Medicaid
- Patient Assistance Programs (PAPs) — provide free drug for uninsured/underinsured patients who meet income criteria
- Manufacturer self-pay rates — some manufacturers offer reduced cash-pay pricing through specific channels
Humira Complete: The $5/Month Copay Card
AbbVie's Humira Complete program offers commercially insured patients a copay card that can reduce their out-of-pocket cost to as low as $5 per month. This is one of the most generous copay card offers in specialty pharma.
Eligibility:
- Must have commercial insurance (employer plan, marketplace plan)
- Not available to patients on Medicare, Medicaid, or any federally funded healthcare program
- Prescription must be for an FDA-approved Humira indication
How to get it:
- Activate at humira.com/humira-complete or call 1-800-4HUMIRA
- Bring the activated card to your pharmacy when filling
Important caveat: The Humira Complete program is a separate program from myAbbVie Assist (the free-drug PAP). As AbbVie winds down PAP support for Humira (new PAP applications close July 1, 2026), the copay card program remains available for now — but its long-term availability is uncertain. Verify current status before relying on it.
Biosimilar Copay Cards: A Comparable Offering
Most major adalimumab biosimilar manufacturers offer copay assistance cards for commercially insured patients. Rates vary but are generally competitive with Humira Complete:
| Biosimilar | Copay Card Offer | Medicare/Medicaid OK? | |---|---|---| | Cyltezo (Boehringer Ingelheim) | $0/month for eligible patients | No | | Hadlima (Organon) | Up to $0 copay, Ready for Health program | No | | Hyrimoz (Sandoz) | Reduced copay, amount varies | No | | Amjevita (Amgen) | $0 copay for eligible commercially insured | No | | Yuflyma (Celltrion) | Copay assistance available | No |
The rule is consistent across brand and biosimilar: copay cards are not available for Medicare or Medicaid patients due to federal anti-kickback laws.
Patient Assistance Programs: Free Drug for Qualifying Patients
If you're uninsured, underinsured, or have Medicare/Medicaid that doesn't cover adalimumab, copay cards don't apply — but PAPs do.
myAbbVie Assist (Humira):
- Provides free Humira to income-qualifying patients
- Closing to new applications July 1, 2026 — apply before this deadline if you want Humira specifically
- Income threshold: typically up to 400% FPL
- Apply at myabbvieassist.com
Cyltezo (Boehringer Ingelheim) PAP:
- Strong PAP offering; Cyltezo is an FDA-interchangeable biosimilar
- GoodRx partnership for uninsured patients
- Apply at cyltezo.com
Hadlima (Organon) PAP:
- Includes free nurse coaching for biosimilar transitions
- Income-based eligibility
- Apply at hadlima.com
Amjevita (Amgen) — Amgen Assist 360:
- Amgen's established patient assistance foundation
- Income-based eligibility, covers commercially uninsured
- Apply at amjevita.com
How Medicare Patients Should Approach This
Medicare patients are excluded from all copay card programs. Your options:
- Medicare Part D $2,100 out-of-pocket cap (2026): New this year — once you've hit $2,100 in covered out-of-pocket costs, your Part D plan covers 100% for the rest of the year.
- Extra Help / Low Income Subsidy: Reduces Part D costs significantly if you meet income/asset thresholds.
- PAP programs: Some PAPs still accept Medicare patients — confirm with the manufacturer whether your Medicare coverage is a disqualifier.
The Decision Framework
Commercially insured with coverage for adalimumab? → Use a copay card (Humira Complete or your biosimilar's equivalent). Takes minutes, effective immediately.
Commercially insured but insurance doesn't cover adalimumab? → Check your plan's prior authorization process first. If denied, apply for a PAP.
Uninsured? → Apply for a PAP directly. Cyltezo and Hadlima have strong programs for uninsured patients; myAbbVie Assist is closing to new applications July 1.
Medicare? → Check Extra Help eligibility first; then check PAP eligibility with manufacturers.
Medicaid (and Medicaid doesn't cover adalimumab in your state)? → See our state-by-state Medicaid coverage guide and check PAP eligibility.
ClariMeds evaluates your eligibility across all of these programs and handles the application for the best fit.
Check your eligibility — takes about 5 minutes
Program terms and eligibility change. Verify current details directly with AbbVie or the relevant biosimilar manufacturer.